Amado, Carlos A.
Martín-Audera, Paula
Agüero, Juan
Lavín, Bernardo A.
Guerra, Armando R.
Muñoz, Pedro
Berja, Ana
Casanova, Ciro
García-Unzueta, Mayte
Funding for this research was provided by:
Instituto de Investigación Marqués de Valdecilla
Article History
Received: 14 May 2022
Accepted: 30 September 2022
First Online: 15 October 2022
Competing interests
: Partially funded by GlaxoSmithKline. Carlos Amado has received speaker or consulting fees from Boehringer Ingelheim, Pfizer, AstraZeneca, Novartis, Chiesi, Faes Farma, Esteve and GlaxoSmithKline. Ciro Casanova has received speaker or consulting fees from AstraZeneca, Bial, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Menarini, Novartis, and research grants from GlaxoSmithKline, Menarini and AstraZeneca. The rest of the authors do not have any conflict of interest.